How big is Tarsus Pharmaceuticals, Inc.?

As of Jun 18, Tarsus Pharmaceuticals, Inc. has a market capitalization of $1.66 billion, with net sales of $233.67 million and a net profit of -$104.94 million over the last four quarters. The company's shareholder's funds are $224.53 million, and total assets amount to $377.35 million.

Market Cap: As of Jun 18, Tarsus Pharmaceuticals, Inc. has a market capitalization of 1,656.20 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Tarsus Pharmaceuticals reported net sales of 233.67 million and a net profit of -104.94 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 224.53 million, while total assets were reported at 377.35 million.

What does Tarsus Pharmaceuticals, Inc. do?

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing treatments for ophthalmic conditions. As of March 2025, it reported net sales of $78 million and a net loss of $25 million, with a market cap of $1.66 billion.

Overview:<BR>Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for ophthalmic conditions within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 78 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,656.20 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -30.08% <BR>Price to Book: 4.84 <BR><BR>Contact Details:<BR>Address: 15440 Laguna Canyon Road, IRVINE CA: 92618 <BR>Tel: 1 949 4099820 <BR>Website: https://www.tarsusrx.com/

Should I buy, sell or hold Tarsus Pharmaceuticals, Inc.?

Is Tarsus Pharmaceuticals, Inc. overvalued or undervalued?

Tarsus Pharmaceuticals, Inc. is considered overvalued and risky due to its high Price to Book Value of 5.39, negative EV to EBIT and EV to EBITDA ratios, and a staggering -1579.81% ROCE, despite a strong one-year stock return of 65.98%.

As of 11 May 2021, the valuation grade for Tarsus Pharmaceuticals, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued given its high Price to Book Value of 5.39 and negative EV to EBIT and EV to EBITDA ratios of -13.83 and -14.01, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -1579.81%, further highlighting the company's struggles.<BR><BR>In comparison to its peers, Tarsus Pharmaceuticals has a P/E ratio of -26.11, while Amneal Pharmaceuticals, Inc. shows a significantly higher P/E of 48.88, and NewAmsterdam Pharma Co. NV has a P/E of -20.32. The company's stock has performed well over the past year with a return of 65.98%, significantly outpacing the S&P 500's 17.14% return, but its year-to-date performance of -2.43% lags behind the S&P 500's 12.22%. Overall, the combination of poor financial metrics and high valuation ratios suggests that Tarsus Pharmaceuticals is overvalued.

Is Tarsus Pharmaceuticals, Inc. technically bullish or bearish?

As of October 3, 2025, Tarsus Pharmaceuticals, Inc. has a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a 1-year return of 99.81% compared to 17.82%.

As of 3 October 2025, the technical trend for Tarsus Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend. Moving averages on the daily chart confirm this bullish sentiment. Although the KST shows a mildly bearish signal on the monthly, the overall Dow Theory is bullish for both weekly and monthly periods. <BR><BR>In terms of performance, Tarsus has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 99.81% compared to the S&P 500's 17.82%, and a 3-year return of 293.46% versus 82.57%.